Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
11. |
ECCT/10/09/05 | A5225/ HiFLAC A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) |
Principal Investigator(s) 1. Deborah Chepngeno langat Site(s) in Kenya 1. |
08-02-2013 |
View |
12. |
ECCT/17/05/03 | TDF IVR-002 Study Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya Partners in Health Research & Development (Thika Partners Clinical Trial Site) |
18-07-2017 |
View |
13. |
ECCT/26/02/07 | IMPAACT 2024 Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV |
Principal Investigator(s) 1. LUCY Chepkurui Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project(KEMRI/WRP) |
27-08-2026 |
View |
14. |
ECCT/22/08/04 | Protocol H06_01TP A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S. flexneri, serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2) |
Principal Investigator(s) 1. Deborah Chepngeno Langat Langat Site(s) in Kenya KEMRI WRP CRC KERICHO |
23-11-2022 |
View |
15. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
27-10-2016 |
View |
16. |
ECCT/24/06/04 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N) (Machakos county) |
23-10-2024 |
View |
17. |
ECCT/25/02/03 | NOZE20240219TB “Validation of a Digital Olfaction Based Breathalyzer Device for Non-Invasive Detection of Volatile Biomarkers in Patients with and without Tuberculosis: Case Control Study”. |
Principal Investigator(s) 1. Ibrahim Daud Site(s) in Kenya KEMRI/WRP CRC Kericho |
15-05-2025 |
View |
18. |
ECCT/16/02/01 | ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘ ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘ |
Principal Investigator(s) 1. ISAIAH MWANGI Site(s) in Kenya 1. lodwar hospital (Turkana county) |
21-03-2016 |
View |
19. |
ECCT/12/12/01 | A pilot study to optimise controlled human malaria infections in humans with varying degrees of prior exposure to malaria using P. falciparum sporozoites administered by needle and syringe |
Principal Investigator(s) 1. Bernhards Ogutu 2. Kevin Marsh Site(s) in Kenya Kenya Medical Research Institute, Centre for Clinical Research, Nairobi |
18-01-2013 |
View |
20. |
ECCT/22/03/03 | HVTN 140/HPTN 101 A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101 |
Principal Investigator(s) 1. Josphat kosgei Site(s) in Kenya KEMRI WRP, KERICHO |
12-05-2022 |
View |